[Combination chemotherapy with mitomycin C, adriamycin and cisplatin (MAP) in advanced adenocarcinoma of the lung: clinical effect and renal toxicity].
Fourteen patients with advanced adenocarcinoma of the lung were treated with a combination chemotherapy of mitomycin C, adriamycin and cisplatin (MAP). The overall response rate was 43% with 6 partial responses. The median duration of response was 5.5 months. The median survival for responders was 17 months, versus 9 months for non-responders. Toxicity included nausea and/or vomiting, alopecia, myelosuppression and renal toxicity. The serial measurement of renal tubular function was found to be useful in detecting renal damage caused by cisplatin containing chemotherapy.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007684:Kidney Tubules / Q000503:physiopathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage
D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin